Current knowledge and future direction of research on soy isoflavones as a therapeutic agents

In the last two decades, accumulating evidence pointed to the importance of autophagy in various human diseases. As an essential evolutionary catabolic process of cytoplasmatic component digestion, it is generally believed that modulating autophagic activity, through targeting specific regulatory actors in the core autophagy machinery, may impact disease processes. Both autophagy upregulation and downregulation have been found in cancers, suggesting its dual oncogenic and tumor suppressor properties during malignant transformation. Identification of the key autophagy targets is essential for the development of new therapeutic agents. Despite this great potential, no therapies are currently available that specifically focus on autophagy modulation. Although drugs like rapamycin, chloroquine, hydroxychloroquine, and others act as autophagy modulators, they were not originally developed for this purpose. Thus, autophagy may represent a new and promising pharmacologic target for future drug development and therapeutic applications in human diseases. Here, we summarize our current knowledge in regard to the interplay between autophagy and malignancy in the most significant tumor types: pancreatic, breast, hepatocellular, colorectal, and lung cancer, which have been studied in respect to autophagy manipulation as a promising therapeutic strategy. Finally, we present an overview of the most recent advances in therapeutic strategies involving autophagy modulators in cancer.

Download Full-text

Laser Welding of Titanium and its Alloys for Medical Applications: Current Knowledge and Future Direction

Materials Science Forum ◽

10.4028/www.scientific.net/msf.618-619.291 ◽

2009 ◽

Vol 618-619 ◽

pp. 291-294 ◽

Cited By ~ 2

Author(s):

Alexander Buddery ◽

Matthew S. Dargusch ◽

David H. StJohn ◽

John Drennan ◽

Samih Nabulsi

Keyword(s):

Laser Welding ◽

Current Knowledge ◽

Medical Applications ◽

Current State ◽

State Of Research ◽

Future Direction

This paper outlines the current state of research into laser welding of titanium and its alloys for medical applications. The differences that exist between the medical and other industries are described and a direction for advancing research in this field is proposed.

Download Full-text

Recent Advances in c-Jun N-terminal Kinase (JNK) Inhibitors

Current Medicinal Chemistry ◽

10.2174/0929867327666200210144114 ◽

2020 ◽

Vol 27 ◽

Cited By ~ 1

Author(s):

Gang Li ◽

Wenqing Qi ◽

Xiaoxun Li ◽

Jinwu Zhao ◽

Meihua Luo ◽

...

Keyword(s):

Mapk Signaling ◽

Therapeutic Agents ◽

Mitogen Activated Protein Kinase ◽

Molecular Scaffolds ◽

Allosteric Inhibitors ◽

Obesity And Diabetes ◽

Mitogen Activated Protein ◽

Jnk Inhibitors ◽

Isoform Selectivity ◽

Future Direction

: c-Jun N-terminal kinases (JNKs), members of the Mitogen-activated protein kinase (MAPK) signaling pathway, play a key role in the pathogenesis of many diseases including cancer, inflammation, Parkinson’s disease, Alzheimer’s disease, cardiovascular disease, obesity, and diabetes. Therefore, JNKs represent new and excellent target by therapeutic agents. Many JNK inhibitors based on different molecular scaffolds have been discovered in the past decade. However, only a few of them have advanced to clinical trials. The major obstacle for the development of JNK inhibitors as therapeutic agents is the JNK-isoform selectivity. In this review, we describe the recent development of JNK inhibitors including ATP competitive and ATP non-competitive (allosteric) inhibitors, bidentate-binding inhibitors and dual inhibitors, the challenges, and future direction of JNK inhibitors as potential therapeutic agents.

Download Full-text

Anti-diabetic potential of Urtica Dioica: current knowledge and future direction

Journal of Diabetes & Metabolic Disorders ◽

10.1007/s40200-021-00942-9 ◽

2022 ◽

Author(s):

Anita Chehri ◽

Reza Yarani ◽

Zahra Yousefi ◽

Tannaz Novin Bahador ◽

Seyed Kazem Shakouri ◽

...

Keyword(s):

Current Knowledge ◽

Urtica Dioica ◽

Future Direction

Download Full-text

Role of Nutraceuticals in Cancer Therapy

Journal of Food Research ◽

10.5539/jfr.v3n4p18 ◽

2014 ◽

Vol 3 (4) ◽

pp. 18 ◽

Cited By ~ 15

Author(s):

Elia Ranzato ◽

Simona Martinotti ◽

Cinzia Myriam Calabrese ◽

Giorgio Calabrese

Keyword(s):

Current Knowledge ◽

Well Being ◽

Therapeutic Agents ◽

Antagonistic Activity ◽

Molecular Processes ◽

Cancer Treatments ◽

Therapeutic Properties ◽

Health And Well Being ◽

Food Value

<p>Nutraceuticals are natural bioactive products with food value and promising therapeutic properties in several diseases. Current cancer treatments, such as chemotherapy, radiotherapy and surgery, induce unintended side effects compromising also health and well-being of patients. Emerging studies suggest that some plant-based agents may impact cellular and molecular processes underlying tumor progression. However, some of these molecules might also play an antagonistic activity against classic therapeutic agents. The aim of this article is to review the current knowledge underpinning the use of nutraceuticals in cancer prevention and therapy.</p>

Download Full-text

Controlled Drug Delivery Vehicles in Veterinary Oncology: State-of-the-Art and Future Directions

Processes ◽

10.3390/pr8050541 ◽

2020 ◽

Vol 8 (5) ◽

pp. 541 ◽

Cited By ~ 1

Author(s):

Patricia de Faria Lainetti ◽

Fernanda Zuliani ◽

Antonio Fernando Leis-Filho ◽

Ricardo Henrique Fonseca Alves ◽

Carlos Eduardo Fonseca-Alves

Keyword(s):

Drug Delivery ◽

Anticancer Agents ◽

Kinase Inhibitors ◽

Current Knowledge ◽

Controlled Drug Delivery ◽

Chemotherapeutic Agents ◽

Drug Delivery Vehicles ◽

Controlled Systems ◽

Delivery Vehicles ◽

Future Direction

Controlled drug delivery systems can be used to carry several anticancer agents, including classical chemotherapeutic agents such as doxorubicin, paclitaxel or cisplatin, and are also used for the encapsulation of tyrosine kinase inhibitors and monoclonal antibodies. Usually, the controlled systems are used to decrease drug toxicity, increase local drug concentration or target specific organs or systems. In dogs, liposomal doxorubicin is the most known controlled drug delivery vehicle in veterinary medicine. However, several antitumor drugs can be encapsulated within these systems. Since the delivery vehicles are a relatively new topic in veterinary oncology, this review aims to discuss the current knowledge regarding the controlled drug delivery vehicles and discuss the current challenges and future direction of its use in veterinary oncology.

Download Full-text

An Overview of Preoperative Glucose Evaluation, Management, and Perioperative Impact

Journal of Diabetes Science and Technology ◽

10.1177/193229680900300605 ◽

2009 ◽

Vol 3 (6) ◽

pp. 1261-1269 ◽

Cited By ~ 26

Author(s):

Ann M. Sheehy ◽

Robert A. Gabbay

Keyword(s):

Glycemic Control ◽

Practice Guidelines ◽

Current Knowledge ◽

Tight Glycemic Control ◽

Prior History ◽

Optimal Care ◽

History Of ◽

Glycemic Targets ◽

Future Direction ◽

National Practice

Perioperative hyperglycemia is a common phenomenon affecting patients both with and without a known prior history of diabetes. Despite an exponential rise in publications and studies of inpatient hyperglycemia over the last decade, many questions still exist as to what defines optimal care of these patients. Initial enthusiasm for tight glycemic control has waned as the unanticipated reality of hypoglycemia and mortality has been realized in some prospective studies. The recent dramatic modification of national practice guidelines to endorse more modest inpatient glycemic targets highlights the dynamic nature of current knowledge as the next decade approaches. This review discusses perioperative hyperglycemia and the categories of patients affected by it. It reviews current recommendations for ambulatory diabetes screening and its importance in preoperative patient care. Finally, it concludes with a review of current practice guidelines, as well as a discussion of future direction and goals for inpatient perioperative glycemic control.

Download Full-text

Microalgae as Contributors to Produce Biopolymers

Marine Drugs ◽

10.3390/md19080466 ◽

2021 ◽

Vol 19 (8) ◽

pp. 466

Author(s):

Rozita Madadi ◽

Hamid Maljaee ◽

Luísa S. Serafim ◽

Sónia P. M. Ventura

Keyword(s):

Food Packaging ◽

Current Knowledge ◽

Polymeric Materials ◽

Current Review ◽

Cultivation Process ◽

Biological Sources ◽

Living Organisms ◽

Future Direction ◽

Insight Into ◽

Microalgae Growth

Biopolymers are very favorable materials produced by living organisms, with interesting properties such as biodegradability, renewability, and biocompatibility. Biopolymers have been recently considered to compete with fossil-based polymeric materials, which rase several environmental concerns. Biobased plastics are receiving growing interest for many applications including electronics, medical devices, food packaging, and energy. Biopolymers can be produced from biological sources such as plants, animals, agricultural wastes, and microbes. Studies suggest that microalgae and cyanobacteria are two of the promising sources of polyhydroxyalkanoates (PHAs), cellulose, carbohydrates (particularly starch), and proteins, as the major components of microalgae (and of certain cyanobacteria) for producing bioplastics. This review aims to summarize the potential of microalgal PHAs, polysaccharides, and proteins for bioplastic production. The findings of this review give insight into current knowledge and future direction in microalgal-based bioplastic production considering a circular economy approach. The current review is divided into three main topics, namely (i) the analysis of the main types and properties of bioplastic monomers, blends, and composites; (ii) the cultivation process to optimize the microalgae growth and accumulation of important biobased compounds to produce bioplastics; and (iii) a critical analysis of the future perspectives on the field.

Download Full-text